Company: DRTSW
Filing Date: 2025-03-12
Form Type: 20-F
Source: 0001213900-25-023187
Chunk: 60

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-03-12
Form: 20-F
Item: Item 3
Chunk 60
---
 and it is difficult to conclusively
assess our freedom to operate without infringing on third-party rights. We may analyze patents or patent applications of our competitors
that we believe are relevant to our activities, and consider that we are free to operate in relation to our product candidates, but our
competitors may obtain issued claims, including in patents we consider to be unrelated to our products or activities, which block our
efforts or may potentially result in our product candidates or our activities infringing such claims. We cannot guarantee that any of
our patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant
patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application
in the United States and abroad that is relevant to or necessary for the commercialization of our product candidates in any jurisdiction.

The scope of a patent claim
is determined by an interpretation of the law, the written disclosure in a patent and the patent’s prosecution history. Our interpretation
of the relevance or the scope of a patent or a pending application may be incorrect. For example, we may incorrectly determine that our
products are not covered by a third-party patent or may incorrectly predict whether a third-party’s pending application will issue
with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider
relevant may be incorrect. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop
and market our products.

Third parties may initiate legal proceedings
alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would
be uncertain. Defending against such lawsuits will be costly and time-consuming, and an unfavorable outcome in that litigation would have
a material adverse effect on our business.

Our commercial success depends
in part on our ability to avoid infringement of the patents and proprietary rights of third parties. There is a substantial amount of
litigation involving the infringement of patents and other intellectual property rights in the biotechnology and pharmaceutical industries.
We may be exposed to, or threatened with, future litigation by third parties having patent or other intellectual property rights and who
allege that our product candidates, uses and/or other proprietary technologies infringe their intellectual property rights. Numerous United
States and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are
developing our